US-based cross-sectional survey in patients taking lasmiditan: Functional REstoration with rEyvow (FREE)

Study identification

• EU PAS number:
  EUPAS37245
• Study ID:
  41778
• Official title and acronym:
  US-based cross-sectional survey in patients taking lasmiditan: Functional REstoration with rEyvow (FREE)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  The objective of the study is to assess patients’ ability to return to their usual daily activities after treating a migraine attack with lasmiditan. Study data will be collected by conducting a 15-minute web-based cross-sectional survey in adult patients in US who have redeemed a REYVOW savings card and have taken lasmiditan at least once in the past month for treatment of a migraine attack.
• Study status:
  Finalised

Research institutions and networks

Institutions

Clinical, Regulatory and Safety, Cerner Enviza

Germany

Study timelines

Date when funding contract was signed

Actual:08/07/2020

Study start date

Actual:16/11/2020

Data analysis start date

Planned:01/12/2020

Actual:01/12/2020

Date of final study report

Planned:01/06/2021

Actual:15/06/2021

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable